Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Igrelimogene litadenorepvec - TILT Biotherapeutics

Next Previous
Drug Profile

Igrelimogene litadenorepvec - TILT Biotherapeutics

Alternative Names: Ad5/3-E2F-d24-hTNFa-IRES-hIL2; TILT 123

Latest Information Update: 16 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TILT Biotherapeutics
  • Developer MSD BV; TILT Biotherapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Interleukin-2 expression stimulants; Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 10 Apr 2024 Efficacy and adverse events data from phase I trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) released by TILT Biotherapeutics
  • 20 Mar 2024 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (Parenteral) (NCT06125197)
  • 08 Dec 2023 Efficacy and adverse events data from a phase I trial in Malignant melanoma released by TILT Biotherapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top